MétaCan
Menu
← Back to cohort

hENT1 gene expression as a predictor of response to gemcitabine and nab-paclitaxel in advanced pancreatic cancer.

2021· article· en· W3168439929 on OpenAlexaff
Sheron Perera, Gun Ho Jang, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Yifan Wang, Mustapha Tehfé, Ravi Ramjeesingh, James Biagi, Bernard Lam, Julie M. Wilson, Faiyaz Notta, Sandra E. Fischer, George Zogopoulos, Steven Gallinger, Robert C. Grant, Jennifer J. Knox, Grainne M. O’Kane

Bibliographic record

VenueJournal of Clinical Oncology · 2021
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsQueen's UniversityCentre Hospitalier de l’Université de MontréalMcGill University Health CentreNova Scotia Cancer CentrePrincess Margaret Cancer CentreOntario Institute for Cancer ResearchToronto General HospitalDalhousie UniversityUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsMedicineGemcitabineFOLFIRINOXOncologyInternal medicinePancreatic cancerRegimenChemotherapyCancerIrinotecan

Abstract

fetched live from OpenAlex

4011 Background: Human equilibrative nucleoside transporter 1 (hENT1) belongs to a family of nucleoside transporters critical to entry of gemcitabine into cells. The prognostic and predictive characteristics of this biomarker in pancreatic ductal adenocarcinoma (PDAC) have primarily been evaluated by immunohistochemistry, with conflicting results. We explored the impact of hENT1 gene expression in the Comprehensive Molecular Characterization of Advanced Ductal Pancreas Adenocarcinoma for Better Treatment Selection (COMPASS) trial. Methods: Patients were enrolled on COMPASS from December 2015 to June 2020 and underwent a biopsy for whole genome sequencing (WGS) and RNA sequencing prior to first chemotherapy in the advanced setting. Biopsies underwent laser capture microdissection to enrich for tumour epithelium. Chemotherapy regimen was determined based on clinician preference. The cut-off thresholds for hENT1 expression were determined using the maximal chi-squared statistic. Response rates and overall survival (OS) were computed based on hENT1 expression and chemotherapy regimen. Results: 254 patients were included in the analyses with a median follow-up time of 18 months. 146 patients were treated with modified FOLFIRINOX (FFX), 104 with gemcitabine and nab-paclitaxel (GnP), and 16 received no systemic therapy. Based on gene expression levels, 133 patients were classified as hENT1 high and 121 as hENT1 low. hENT1 expression was significantly associated with the modified Moffitt classifier with higher expression seen in classical tumours (p < 0.001). In the entire cohort, median OS was 10.0 months in hENT1 high vs. 8.3 months in hENT1 low (adjusted HR 0.78, 95% confidence interval 0.59 - 1.03, p = 0.08). In patients receiving modified FFX, there was no difference in response rates (32% vs. 31%, p = 1.00) or OS (10.6 vs. 10.6 months, p = 0.94) between the hENT1 high and hENT1 low groups, respectively. However, in patient treated with GnP, response rates were significantly higher in hENT1 high patients compared to those with hENT1 low tumors (45% vs. 21%, p = 0.035). Median OS in this GnP treated cohort was 9.8 months in hENT1 high vs. 6.1 months hENT1 low (p = 0.003). In an interaction analysis, hENT was predictive of treatment response to GnP (p = 0.0002). Conclusions: Biomarkers predictive of response to GnP and FFX are urgently needed. Here we demonstrate that hENT1 gene expression is a predictor of response to GnP in advanced PDAC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.103
GPT teacher head0.515
Teacher spread0.411 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicPancreatic and Hepatic Oncology Research→French-language works237,207→